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Proteinmicroarray-basedapproachesareincreasinglybeingusedinresearchandclinicalapplicationstoeitherproﬁletheexpression
of proteins or screen molecular interactions. The development of high-throughput, sensitive, convenient, and cost-eﬀective formats
for detecting proteins is a necessity for the eﬀective advancement of understanding disease processes. In this paper, we describe
the generation of highly multiplexed, antibody-based, speciﬁc, and sensitive protein microarrays coupled with rolling-circle signal
ampliﬁcation (RCA) technology. A total of 150 cytokines were simultaneously detected in an RCA sandwich immunoassay format.
Greater than half of these proteins have detection sensitivities in the pg/mL range. The validation of antibody microarray with
human serum indicated that RCA-based protein microarrays are a powerful tool for high-throughput analysis of protein expression
and molecular diagnostics.
INTRODUCTION
Despite great advancements in genomics research,
DNA microarrays are still of limited applicability as di-
agnostic tests, in part because proteins, not genes, are
the ultimate eﬀectors of a biological process. Proteins
are often expressed at concentrations and varied struc-
tural forms having modiﬁcations that cannot be pre-
dicted from mRNA analysis. There is a great deal of in-
terest in proteomics-based approaches that enable proﬁl-
ingtheabundanceofproteins,orinvestigationofprotein-
protein and protein-drug interactions. The concept of a
proteinmicroarrayorbiochipisattractiveforrapid,high-
throughput proteomics studies that utilize available sam-
plevolumes [1,2,3,4].P r ot einsthatar ep r ese ntinab no r -
mal concentrations (increased or decreased) in a disease
state could be identiﬁed and validated as disease mark-
ers. Proteomics pattern analysis based on a multiplexed
list of biomarkers may well make possible the diagnosis of
certain diseases that do not have either eﬀective screening
options or biomarkers already detected by conventional
immunoassays [5]. Identiﬁcation of such disease markers
willprovidevaluableinformationfordetection, classiﬁca-
tion, and prognosis of diseases, as well as targets for treat-
ment outcomes. High-throughput protein chips require
arraying a wide range of probes that speciﬁcally recog-
nize a single protein in complex mixtures such as serum,
plasma, and other biological specimens. These probes are
mostfrequentlyantibodiesorantibodymimics[3,4,6,7].
Given the immense promise of proteomics technolo-
gies, there are still limitations that need to be over-
come, such as lack of sensitivity and enhanced informa-
tion about the target. Because there is no PCR equivalent
available to amplify proteins, the identiﬁcation of low-
abundance proteins may often be diﬃcult or impossible,
and important biomarker information could thus be lost.
Rolling-circle ampliﬁcation (RCA) is a unique signal am-
pliﬁcation technology [8] that permits detection of mul-
tiple proteins with a broad dynamic range on protein mi-
croarrays [4, 9]. In this paper, we describe the develop-
ment of RCA-based highly multiplexed and sensitive pro-
tein microarray immunoassays for detecting 150 proteins
in an ELISA format. Application to human serum and
plasma samples has established that the rolling-circle am-
pliﬁed protein microarray is a powerful tool for the pro-
ﬁling of expressed proteins in biological specimens.
MATERIAL AND METHODS
Preparation of microarrays. Glass slides were pre-
pared and silanized according to procedures previously
described [10]. Antibodies (R&D Systems, Minneapolis,
Minn; Pharmingen, San Diego, Calif; BioSource Inter-
national, Camarillo, Calif) were diluted to 0.5mg/mL in
PBS containing 0.05mg/mL BSA, and 375pL of each was
spotted in quadruplicate onto the slides using a BioChip
Arrayer (Packard BioSciences, Downers Grove, Ill). Each
spot has a diameter of approximately 180µmw i t ha300 Weiping Shao et al 2003:5 (2003)
center-to-centerspacingof270µm.Eachslidewasdivided
by a teﬂon mask into 16 subarrays, each with a diameter
of 0.65cm. Within each subarray, 256 spots were printed
at known locations, containing 40 diﬀerent features (anti-
bodies for speciﬁc antigens) in quadruplicate (160 spots).
The remaining features comprised of controls for anti-
body immobilization, Cy5-labeled mouse IgG and inter-
nal calibrators (biotin mouse IgG).
RCA microarray immunoassays. Slides were blocked
by adding 30µL blocking buﬀer (0.5% nonfat dry milk,
0.2% BSA, and 0.05% Tween-20 in PBS) to each subar-
ray and incubating for 1 hour at 37◦C in a humidiﬁed
chamber, and then washed by immersion in PBS contain-
ing 0.5% Brij 35 for 2 minutes. A 15µL aliquot of sam-
ple (single analyte or mixture of multiple analytes; serum,
plasma,orculturesupernatant)wasimmediatelyaddedto
eachsubarray,incubatedfor30 minutes at37◦C,andthen
washed as described above. After analytes were captured,
a2 0µL aliquot of the appropriate mixture of biotinylated
detection antibodies at 0.1µg/mL each was applied to in-
dividual arrays and incubated at 37◦Cf o r3 0m i n u t e si n
a humidiﬁed chamber. Slides were washed twice for two
minutes in PBS containing 0.5% Brij 35. A mouse mono-
clonalantibiotinantibody-primerconjugatewasprepared
by derivatization of a mouse monoclonal antibiotin IgG
(JacksonImmunoResearchLaboratories,Inc,WestGrove,
Pa) with a 5’-terminal amine-modiﬁed oligonucleotide
primer, 5’-Thiol-AAA AAA AAA AAA AAA CAC AGC
TGA GGA TAG GAC AT-3’, as previously described [9].
The conjugate was annealed with 75nM circle 1 (cyclic
5’-CTC AGC TGT GTA ACA ACA TGA AGA TTG TAG
GTC AGA ACT CAC CTG TTA GAA ACT GTG AAG
ATC GCT TAT TAT GTC CTA TC-3’) in PBS contain-
ing 0.05% Tween-20 and 1mM EDTA at 37◦Cf o r3 0
minutes. Twenty microliters of the conjugate-circle mix-
ture was applied to each array. Slides were incubated at
37◦C for 30 minutes and then washed twice. RCA re-
action mixture (20µL) containing native T7 DNA poly-
merase(20U/mL),1mMdNTPs,ssDNA-binding protein
22µg/mL, 1x sequenase buﬀer, 8% DMSO, and 0.05mM
Cy5 decorator (5’-Cy5-TGT CCT ATC CTC AGC TGG-
Cy5) was added to each subarray. Slides were incubated
at 37◦C for 45 minutes, then washed twice in PBS con-
taining 0.5% Brij 35 and once in PBS, and spin-dried. Ar-
rays were analyzed on an Axon GenePix 4000B scanner
(Axon Instruments Inc, Foster City, Calif), and ﬂuores-
cence quantitated by using GenePix Pro 3.0 quantitation
software. Data was analyzed by using MSI Analyzer soft-
ware (Molecular Staging, Inc).
RESULTS AND DISCUSSION
Fabricationofantibodymicroarray
Microarrays were printed on cyanosilane-coated glass
slides. This surface was chosen based on experiments
indicating that cyanosilane-activated slides have the ad-
vantages of (1) simpler preparation, (2) less-expensive
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Figure 1. Schematic representation of microarray immunoas-
say with RCA signal ampliﬁcation. It consists of (a) analyte
capture by antibody immobilized on microarray, (b) detection
by biotinylated secondary antibody, (c) binding of antibiotin
antibody-oligonucleotide conjugate pre-annealed with circle 1,
and (d) rolling-circle replication to generate long single-strand
DNA which is hybridized with oligonucleotide decorator.
reagents, and (3) more uniformity of bound antibody
spot morphology over thiolsilane-coated and cross-linker
(such as GMBS) activated glass slides (data not shown).
The concentration of capture antibody for printing was
optimized by comparing speciﬁc signal intensities from
the same capture antibody printed on the chip at diﬀer-
ent concentrations chosen for microarray printing. Spe-
ciﬁc signals at 0.5mg/mL reached the point of saturation
(data not shown), indicating that antibodies saturated the
area available for immobilization in the spot. The unifor-
mity of antibody immobilization on the chip was assessed
by measuring the coeﬃcient of variation (CV) from the
quadruplicate spots using Cy5-labeled anti-isotype anti-
bodies (against the species used in the capture antibod-
ies), previously reported as approximately 10% for each
feature on the chip[4].
Improvingthesensitivityofproteindetection
onantibodyarray
Rolling circle ampliﬁcation enables ampliﬁcation of
signals tethered to proteins and nucleic acids [4, 9, 11].
Immunoassays incorporating RCA have shown a large in-
crease in sensitivity when compared with the direct as-
say [4]. The technique consists of protein capture by an-
tibody immobilized on microarrays, detection by biotin-
labeled second antibody speciﬁc for the captured protein,
bindingofauniversalantibiotinantibodyoligonucleotide
conjugate pre-annealed with circle, and RCA signal am-
pliﬁcation where a long single-strand DNA is generated
by rolling-circle replication in the presence of DNA poly-
merase and nucleotides, with hybridization of the RCA
product to ﬂuorescent-labeled complementary oligonu-
cleotide probes occurring simultaneously (Figure 1).
Besides the signal ampliﬁcation by RCA, the sensitiv-
ity of the antibody array was further improved by two2003:5 (2003) RCA Enhanced Comprehensive Proteomic Proﬁling 301
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Figure 2. Optimization of antibodies from diﬀerent sources (A
and B) for choosing optimal pair for immunoassay on protein
microarray with examples of (a) IL-13 and (b) MCP-2.
approaches: (1) choosing optimal capture and detection
antibody pairs for the microarray immunoassay and (2)
optimizing assay procedures.
Antibody microarray development commenced with
selection of optimal antibody pairs. For individual fea-
tures, if the matched antibody pair developed for conven-
tional ELISA was available, it was preferentially selected
for the chip development. However, in terms of sensi-
tivity and speciﬁcity, antibody pairs do not always func-
tion equivalently on plastic ELISA plates and the glass-
based microarrays. Antibody pairs from diﬀerent man-
ufacturers for the same antigen with similar sensitivity
as ELISA assays perform quite diﬀerently in microarrays.
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Figure 3. Titration of SSB in the RCA reaction mixtures. Cy-
tokine IL-8 and Eot-2 at 100pg/mL were detected.
Thus it has become necessary to select optimal pairs for
antibody microarrays by comparing all available antibod-
ies and pairs. As an example, Figure 2a shows the diﬀer-
encebetweentwomatchedpairsofantibodies(forELISA)
from diﬀerent sources with speciﬁcity for detecting the
cytokine IL-13 using the antibody microarray. The pair
from source A showed strong signal intensity with a sen-
sitivity of less than 100pg/mL. However, the pair from
source B did not show signal even at concentrations as
high as 5ng/mL IL-13. Selecting the antibody pair from
source A provided at least 50-fold increase of sensitivity
when compared with the pair from source B. Alterna-
tively, the ELISA antibody pair from the same set is not
always the optimal for a microarray immunoassay. One
example shown in Figure 2b is for the chemokine MCP-
2. Neither of the ELISA-matched pairs showed sensitiv-
ity better than 100pg/mL on the microarray slides. How-
ever, using a capture antibody from A and a detection an-
tibody from B, the sensitivity for MCP-2 was improved
to 10pg/mL or better, a 10-fold increase in sensitivity
relative to a single manufacturer’s reagents. For features
without matched pairs, monoclonal antibodies with dif-
ferent binding epitopes or polyclonal antibodies were ex-
tensivelyevaluatedforsensitivityrangespermittingdetec-
tionofbiologicallyrelevantchangesinproteinexpression.
Cross-reactivity and nonspeciﬁc signals were also exten-
sively evaluated as described below.
The second approach of improving sensitivity was to
optimize the assay procedures. This involved optimizing
detection antibody concentrations, conjugate and circle
concentrations, incubation temperatures and time, and
RCA reaction solution composition. Analogous to sand-
wich ELISA assays, the conditions giving the best signal to
noise ratio were found to be 0.1µg/mL of detector with
assay incubation time of 30 minutes at 37◦C. Titration of
conjugate and circle pre-annealed to conjugate revealed
the optimal concentration to be 2µg/mL conjugate with
75nM circle. Other components, such as the concentra-
tion of single-strand DNA binding protein (SSB), were
also optimized for maximum sensitivity in RCA reaction
mixtures (Figure 3).302 Weiping Shao et al 2003:5 (2003)
Table 1. Performance characteristics of the 150-feature protein microarray.
Analyte Biological ED50 (pg/mL) Mean serum levels (pg/mL) Array sensitivity (pg/mL) ELISA sensitivity (pg/mL)
ALCAM na 52000 100 24
ANG na 360000 10 6
AR 5000–15000 45.4 100 na
BDNF 3000–10000 27793 10 20
BLC 5000–20000 na 10 na
SVE-cadherin na 2800 1000 313
CCL28 400000–2000000 43.8 30 2.58
SCD23 na 1.3IU/mL 10000 0.15U/mL
CD27 na na 100 na
CD30 30000–100000 6.4U/mL 10 na
CD40 na 102.1 300 15.6
CNTF 50000–150000 nd 300 8
CNTF Rα 200000–400000 na 100 na
CT-1 1000–4000 619.5 1000 na
CTACK 100000–400000 522 10 1.55
CTLA-4 2000000–4000000 nd 1000 313
DR6 na na 10 na
EGF 100–400 336 10 0.7
ENA-78 3000–15000 1449 100 15
Eot 10000–20000 68.6 10 5
Eot-2 10000–50000 249 10 1.83
Eot-3 250000–1000000 9.7 100 2
Fas 10000–40000 9406 100 20
Fas ligand 200000–500000 nd 100 100
FGF acidic 100000–300000 na 10 na
FGF basic 100000–250000 nd 100 3
FGF-4 50–150 93.8 300 30
FGF-6 100–300 na 100 na
FGF-7 15000–25000 < 31.21 0 1 5
FGF-9 1000–2000 na 100 na
Flt-3 L 500–1000 93.9 10 7
Follistatin 100000–400000 2483 30 29
G-CSF 20–60 22 1000 20
GCP-2 na 156 100 1.6
GDNF 1000–3000 na 10 na
GM-CSF 20–80 1.72 10 3
Sgp130 3000–9000 306000 100 80
GRO-α 1000–4000 93 10 10
GRO-β 3000–300000 na 10 na
GRO-γ 10000–100000 na 10 na
HB-EGF 2000–5000 na 100 na
HCC-1 200000–8000000 na 30 na
HCC4 150000–750000 na 100 na
HGF 20000–40000 721 100 40
HVEM 500000–2000000 na 30 na
ICAM-1 na 211000 10 350
ICAM-3 na 50000 100 580
IFN-α 3.8 ×108 U/mg < 10 100 15.6
IFN-γ 800–1500 < 15.61 0 8
IFN-ω na nd 100 9.3752003:5 (2003) RCA Enhanced Comprehensive Proteomic Proﬁling 303
Table 1. Continued.
IGF-I 1000–3000 105000 100 26
IGF-IR na na 100 na
IGF-II 5000–10000 29300 1000 na
IGFBP-1 1000000–4000000 14300 30 na
IGFBP-2 30000–90000 434200 100 na
IGFBP-3 50000–150000 2375000 1000 50
IGFBP-4 30000–90000 na 100 na
I-309 3000–9000 nd 10 0.71
IL-1α 3.0–7.0 < 3.91 0 1
IL-1β 13–20 0.536 10 1
IL-1rα 20000–60000 418 100 22
IL-1 sRI 500000–1000000 na 100 na
IL-1 sRII 1000000–5000000 11000 10 10
IL-2 250–500 1.6 10 7
IL-2 Rβ 1000000–3000000 na 300 na
IL-2 sRa 500000–1000000 1346 10 10
IL-2 Rγ 3000000–6000000 na 30 na
IL-3 100–400 < 31.2 1000 7.4
IL-4 50–200 < 0.25 10 10
IL-5 100–200 < 7.81 0 3
IL-5 Rα 200000–300000 na 100 na
IL-6 200–800 1.62 10 0.7
IL-6 sR 5000–15000 31000 10 7
IL-7 200–500 2.82 10 0.1
IL-8 100–500 13.2 1 10
IL-9 500–1000 na 1000 na
IL-10 500–1000 2 10 3.9
IL-10 Rβ na na 10 na
IL-11 60–240 < 31.2 100 8
IL-12 (p40) 50–200 77 10 15
IL-12 (p70) 50–200 1.93 10 0.5
IL-13 3000–6000 < 62.51 0 3 2
IL-15 500–2000 2.14 100 2
IL-16 2000000–10000000 171 100 6.2
IL-17 2000–6000 < 31.21 0 1 5
IL-18 na 126 100 12.5
IL-21 10000–40000 na 300 na
IP-10 20000–60000 89 10 1.7
I-TAC 1000–5000 177 10 13.9
Leptin/OB 400–2000 4760(M), 20676(F) 3000 7.8
LIF 500 na 100 8
SLIF-Rα 3000000–6000000 4300 300 156
Lymphotactin 50000–200000 na 100 na
M-CSF 500–1500 670 10 9
M-CSF R 4000–12000 na 300 na
MCP-1 5000–20000 370 10 5
MCP-2 30000–120000 200 10 na
MCP-3 20000–80000 < 15.61 0 2
MCP-4 200000–400000 na 300 na
MDC 3000–9000 1089 10 62.5
MIF 50000–100000 1337 100 na304 Weiping Shao et al 2003:5 (2003)
Table 1. Continued.
MIG 200000–600000 914 10 na
MIP-1α 2000–10000 < 46.91 0 1 0
MIP-1β 10000–30000 80 10 11
MIP-1δ 2000–4000 na 100 na
MIP-3α 500–2000 26.3 30 0.47
MIP-3β 100000–300000 na 10 na
MMP-1 na 6490 300 52
MMP-2 na 1169000 300 na
MMP-7 na 2290 100 16
MMP-9 na 436000 300 156
MMP-10 na 770 100 4.13
MPIF 200000–500000 536 100 3.3
MSP 10000–30000 4nM 100 na
NAP-2 100000–300000 na 100 na
β-NGF 800–1500 265 10 na
NT-3 10000–30000 13.4 100 na
NT-4 5000–15000 na 10 na
OSM 150–300 < 15.61 0 n a
PARC 500000–2000000 na 100 na
PDGF-Rα 5000000–10000000 na 3000 na
PECAM-1 na 20000 1000 na
PF4 5000000–15000000 14700 300 na
PlGF na 18 10 7
Prolactin 30–100 9300 1000 7.6mIU/L
RANK 4000–10000 na 300 na
RANTES 1000–5000 49137 10 8
SCF 2500–5000 984 10 9
SCF R 2000000–6000000 na 100 na
SDF-1α 3000–9000 2000 10000 18
SDF-1β 10000–30000 na 10000 na
L-Selectin na 954000 10 300
ST2 na 500 30 na
TARC 3000–9000 331 100 5
TGF-α 100–400 22 100 na
TGF-β1 20–60 48600 10 7
TGF-β3 10.0–30.0 2400 10 na
TIMP-1 8nM 190000 30 80
TIMP-2 na 106000 10 na
TNF-α 20–50 1.25 3 4.4
TNF-β 20–50 < 156 10 16
TNF RI 45000–90000 1198 10 3
TNF-RII 4000–16000 1725 100 1
TRAIL 4000–12000 nd 5000 120
TRAIL R1 1000–3000 na 10 na
TRAIL R4 30000–60000 na 100 na
UPAR 50000–150000 2370 100 33
SVAP-1 na 125900 100 300
VEGF 2000–6000 220 10 9
VEGF-R2 4000–8000 9768 1000 4.62003:5 (2003) RCA Enhanced Comprehensive Proteomic Proﬁling 305
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Figure 4. Cross-reactivity of capture antibodies and analytes ((a) and (c)), capture antibodies and detection antibodies ((b) and (d))
on the subarrays 3 (A) and 4 (B). Each subarray was printed with about 35 diﬀerent capture antibodies (listed on the chart). Cross-
reactivity was determined by using diﬀerent matched secondary antibody and 50ng/mL or 0ng/mL of its cognate analyte, which has
been described in the text. A shaded square oﬀ the diagonal indicates the presence of nonspeciﬁc signals (intensity ≥ 300). None of
these nonspeciﬁc signals exceed the intensity of 600 ﬂuorescence intensity units (images are scanned at PMT of 600 and power of
100% on Axon scanner).
The analytical sensitivity of the microarray im-
munoassay was determined by using serial dilutions of
each single puriﬁed antigen. The sensitivity of detection,
deﬁned as the lowest concentration that delivered clear
speciﬁc signal intensity above detection threshold (mean
intensity of the negative control plus 2 SD), was calcu-
lated. Sixty-ﬁve (43%) of the 150 cytokine features had a
sensitivity of ≤ 10pg/mL, 52 (35%) had a sensitivity of ≤
100pg/mL, 27 (18%) had a sensitivity of ≤ 1000pg/mL,
and 6 (4%) had a sensitivity of ≥ 1,000pg/mL (Table 1).
Sixty-two of the cytokines represented on the chip are
unique, with no corresponding commercially available
ELISA kits. The sensitivity goal for these arrays was ad-
equacy to detect biologically relevant (ie, 2-fold) increases
in cytokine level above normal values in clinical ﬂuids in-
cluding serum and plasma.
Speciﬁcityofantibodymicroarray
Although antibodies are highly speciﬁc for their re-
spective cognate proteins, it is possible that structurally
related proteins might have similar epitopes. Cross-
reactivity or nonspeciﬁc signals between immobilized306 Weiping Shao et al 2003:5 (2003)
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Figure 5. Protein expression proﬁling of normal human serum (Sigma) on 70-feature antibody microarray. Speciﬁc signals detected
were consistent with the protein level in serum. (a) Images of detecting 70 proteins in antibody microarray obtained with Axon
microarray scanner. (b) Fluorescence intensities were derived from microarray images with averaging four spots of the same feature.
capture antibodies and antigens or detection antibodies
for 150 features were determined in three diﬀerent ways.
First, the cross-reactivity of individual antigens or detec-
tionantibodies wasdeterminedbyanalyzingasingleanti-
gen at 0 and 50ng/mL with its corresponding paired de-
tection antibody. Any signals on the 0ng/mL array were
categorized as cross-reactivity between the detection and
captureantibodies.With50ng/mLanalyte,signalsshould
have only been observed at the speciﬁc locations. Other
signals after background subtraction (the 0ng/mL ar-
ray) were assumed to be cross-reactivity from the analyte.
Nonspeciﬁc signals were eliminated by segregating all fea-
tures into multiple subarrays, thus the capture antibodies
producing nonspeciﬁc signals were physically separated
from those particular detection antibodies or antigens.
This also allowed simultaneous detection of both compo-
nents of a biological signaling system, such as a growth
factor and its receptor.
Residual cross-reactivity and nonspeciﬁc signals were
ﬁrst minimized by optimization of washing and blocking
conditions [4]. Next, a mixture of several analytes at con-
centrations of 10ng/mL each was applied to the chip,2003:5 (2003) RCA Enhanced Comprehensive Proteomic Proﬁling 307
followed by detection with the complete detection anti-
body cocktail. Signals were only observed where both the
analyte and its speciﬁc detection antibody were present.
Then a mixture of all analytes in the subarray at 10ng/mL
each was added to the microarray, but detection was with
an incomplete cocktail of antibodies. Signals were only
detected on those features corresponding to the speciﬁc
detection antibodies added. As shown in Figure 4,b o t h
cross-reactivity between capture antibodies and analytes
and cross-reactivity between capture antibodies and de-
tection antibodies in each subarray were minimized. Ap-
proximately 99% of nonspeciﬁc binding pairs had ﬂuo-
rescence intensity units of less than 300, used as the back-
groundsignalminimum during thedataquantitation. In-
terferences from biological specimen were screened using
normal human serum and single detectors (biotinylated
detection antibody) corresponding to each feature on the
chip. Only speciﬁc signals of the proteins present in the
specimen were detected by their associated detector an-
tibody. Other nonspeciﬁc signals or background signals
were negligible.
Validationoftheantibodymicroarray
Theantibodymicroarraywasvalidatedbyrunningas-
says with normal human serum (Sigma, St. Louis, Mo) on
our 70-feature protein chip. We simultaneously detected
70 proteins in normal human serum. Signals correspond-
ing to speciﬁc proteins were identiﬁed (Figure 5), which
are consistent with their presence with signiﬁcant level in
thenormalhumanserum(Table 1).Proteinswithlowﬂu-
orescence signal intensities agree with their very low level
in serum (if present), indicating that our antibody mi-
croarray provides a speciﬁc, robust, and high-throughput
approach for global analysis of protein expression.
CONCLUSION
Immunoassays on microarrays hold appeal for studies
requiring the ability to quantify many selected proteins
simultaneously. Considerable progress has been made in
this area recently in terms of increased assay sensitivity
andcomplexity(ie,degreeofmultiplexing).Rolling-circle
ampliﬁcation facilitates the use of such arrays with its
powerful degree of signal enhancement and simultaneous
detection of a large number of deﬁned analytes. Such ro-
bust systems will enable routine use of antibody arrays in
both research and diagnostic modalities.
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